Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases

AIMS: Rituximab is a chimeric IgG‐1 monoclonal antibody that depletes B cells, aiding in the treatment of several conditions including autoimmune diseases. It is not licensed for use in children. This study aimed to quantify the B cell‐related pharmacodynamics of rituximab in children with autoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Shan, Yu, Huixin, Surti, Ayesha, Cheng, Iek, Marks, Stephen D., Brogan, Paul A., Eleftheriou, Despina, Standing, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624401/
https://www.ncbi.nlm.nih.gov/pubmed/31026092
http://dx.doi.org/10.1111/bcp.13970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624401/
https://www.ncbi.nlm.nih.gov/pubmed/31026092
http://dx.doi.org/10.1111/bcp.13970

Ejemplares similares